Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 3/20 | 0.36 |
| ▸ | RARA | P10276 | 3/20 | 0.36 |
| ▸ | RARB | P10826 | 3/20 | 0.36 |
| ▸ | RARG | P13631 | 3/20 | 0.36 |
| ▸ | APP | P05067 | 4/20 | 0.35 |
| ▸ | BACE1 | P56817 | 4/20 | 0.35 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17729307 | 0.80 | AKR1B1 (0.55) | AKR1B1RARARARBRARGAPP | |
| SCHEMBL3167971 | 0.80 | RARA (0.39) | AKR1B1RARARARBRARG | |
| SCHEMBL30353277 | 0.77 | AKR1B1 (0.35) | AKR1B1AKR1B10MAPTAKR1A1 | |
| SCHEMBL17729317 | 0.75 | ITGB2 (0.43) | AKR1B1 | |
| SCHEMBL30353235 | 0.75 | AKR1B1 (0.33) | AKR1B1AKR1B10MAPTAKR1A1 | |
| SCHEMBL28769907 | 0.73 | AKR1B1 (0.32) | AKR1B1RARARARBRARG | |
| SCHEMBL17729340 | 0.72 | AKR1B1 (0.35) | AKR1B1APPBACE1AKR1B10MAPT | |
| SCHEMBL3421790 | 0.72 | NOTUM (0.49) | RARARARBRARGBACE1 | |
| SCHEMBL23362552 | 0.70 | MAPT (0.43) | BACE1MAPT | |
| SCHEMBL17922651 | 0.69 | PTGER4 (0.38) | AKR1B1RARARARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100145056-A1 | ACETYL 2-HYDROXY-1,3-DIAMINOALKANES | JOHN VARGHESE | 2010-06-10 | — | — | US | disclosed |
| US-7645780-B2 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7544717-B2 | 2-amino- and 2-thio- substituted 1,3-diaminopropanes | ELAN PHARMACEUTICALS, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| CN-100384824-C | Acetyl 2-hydroxy-1, 3-diaminoalkanes | PHARMACIA & UPJOHN CO LLC (US) | 2008-04-30 | — | — | CN | disclosed |
| US-20070293483-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | disclosed |
| EP-1565443-A4 | ACETYL 2-HYDROXY-1,3 DIAMINOALKANES | ELAN PHARM INC (US) | 2007-07-18 | — | — | EP | disclosed |
| US-7244725-B2 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1751091-A2 | 2-AMINO- AND 2-THIO-SUBSTITUTED 1,3-DIAMINOPROPANES | Elan Pharmaceuticals, Inc. (US) | 2007-02-14 | — | — | EP | disclosed |
| EP-1734961-A2 | METHODS OF TREATMENT OF AMYLOIDOSIS USING BI-CYCLIC ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20050267199-A1 | 2-Amino- and 2-thio- substituted 1,3-diaminopropanes | ELAN PHARMACEUTICALS, INC. | 2005-12-01 | — | — | US | disclosed |
| US-20050239832-A1 | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| WO-2005095326-A2 | 2-AMINO- AND 2-THIO-SUBSTITUTED 1,3-DIAMINOPROPANES | ELAN PHARMACEUTICALS, INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005087714-A2 | METHODS OF TREATMENT OF AMYLOIDOSIS USING BI-CYCLIC ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| EP-1565443-A2 | ACETYL 2-HYDROXY-1,3 DIAMINOALKANES | Elan Pharmaceuticals, Inc. (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20040180939-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS INC. | 2004-09-16 | — | — | US | disclosed |
| WO-2004024081-A2 | ACETYL 2-HYDROXY-1,3 DIAMINOALKANES | ELAN PHARMACEUTICALS, INC. (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145056-A1 | ACETYL 2-HYDROXY-1,3-DIAMINOALKANES | BACE1, BACE2, APP | AKR1B1 1647/4885RARA 3617/4885RARB 3071/4885 |
| US-20040180939-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | BACE1, BACE2, APP | AKR1B1 1877/4885RARA 3617/4885RARB 3069/4885 |
| US-20050239832-A1 | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors | APP, DNPEP, BACE1 | AKR1B1 1006/4885RARA 3993/4885RARB 3511/4885 |
| US-20050267199-A1 | 2-Amino- and 2-thio- substituted 1,3-diaminopropanes | BACE1, APP, BACE2 | AKR1B1 3613/4885RARA 3795/4885RARB 2991/4885 |
| US-20070293483-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | BACE1, BACE2, APP | AKR1B1 1647/4885RARA 3617/4885RARB 3071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.